Whooping cough—a continuing problem: Pertussis has re-emerged in countries with high vaccination coverage and low mortality

BMJ

Volumn 324, Issue 7353, 2002, Pages 1537-1538

  Crowcroft, N S ^a   Britto, Joseph ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADULT; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CHILD; CHILDHOOD MORTALITY; COST BENEFIT ANALYSIS; DRUG EFFICACY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFANT; INFANT MORTALITY; PERTUSSIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEROLOGY; VACCINATION;

COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 0037193825     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.324.7353.1537     Document Type: Editorial

References (12)

1. World Health Organization. World Health Report 2001. Mental health: new understanding, new hope. www.who.int/whr/2001/main/en/pdf/annex2.en.pdf (accessed 7 Jun 2002).
2. World Health Organization. Department of Vaccines and Biologicals. Pertussis surveillance. A global meeting. WHO/V&B/01.19. Geneva, 2001.
3. Skrowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002; 185: 1448–1453.
4. Mooi FR, Van Oirschot H, Heuvelman K, Van der Heide HGJ, Gaastra W, Willems RJL. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: Temporal trends and evidence for vaccine-driven evolution. Infect Immunity 1998; 66: 670–675.
5. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults 1989–98. J Infect Dis 2000; 182: 1409–1416.
6. Gzyl A, Augustynowicz E, van Loo I, Slusarczyk. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 2002; 20: 299–303.
7. Njamkepo E, Rimlinger F, Thiberge S, Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002; 20: 1290–1294.
8. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 2001; 69: 5520–5528.
9. Ranganathan S, Tasker R, Booy R, Habibi P, Nadel S, Britto J. Pertussis is increasing in unimmunized infants: is a change in policy needed? Arch Dis Child 1999; 80: 297–299.
10. Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9: 863–866.
11. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 2002; 20: 1316–1330.
12. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32: 1691–1697.